Development of a transdermal gel for reversible male contraception
Contraception · 2025
DOI: 10.1016/j.contraception.2025.110830 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Contraception, 2025. Verfasst von Regine Sitruk-Ware und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomedical Research, Population Council, New York, NY, United States. Electronic address: regine@popcouncil.org. Hauptthemen laut MEDLINE: Contraceptive Agents, Male, Testosterone, Norprogesterones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Population Council.
Abstract (Originalsprache)
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries. Available reversible options for male contraception include male condoms or withdrawal, both with high typical use failure rates, and vasectomy, which is not easily reversible. Advanced methods of male hormonal contraception include combinations of progestin and androgen, generally testosterone itself. Administration of these steroids results in the suppression of gonadotropins leading to the suppression of sperm production with full reversibility within a few months. Importantly, the exogenous androgen replaces the suppressed endogenous testosterone, minimizing side effects for the user. Using the skin to deliver steroids in the systemic circulation is a well-accepted concept both for the treatment of hypogonadism and contraception. A transdermal gel delivering Nestorone (segesterone acetate) and testosterone is under development and is leading the way in advancing novel, self-delivered methods of male hormonal contraception.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Biomedical Research, Population Council, New York, NY, United States. Electronic address: regine@popcouncil.org.
- Contraceptive Development Program, Division of Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States.
- Department of Medicine, University of Washington, Seattle, WA, United States.
- Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, United States; Clinical and Translational Science Institute, The Lundquist Institute at Harbor-UCLA…
Förderung
- Intramural NIH HHS
- Population Council
Zitieren
APA
Sitruk-Ware, R., Blithe, D. L., Page, S. T., & Wang, C. (2025). Development of a transdermal gel for reversible male contraception. Contraception. https://doi.org/10.1016/j.contraception.2025.110830
Vancouver
Sitruk-Ware R, Blithe DL, Page ST, Wang C. Development of a transdermal gel for reversible male contraception. Contraception. 2025. doi:10.1016/j.contraception.2025.110830
BibTeX
@article{SitrukWare2025,
author = {Sitruk-Ware, Regine and Blithe, Diana L and Page, Stephanie T and Wang, Christina},
title = {Development of a transdermal gel for reversible male contraception},
journal = {Contraception},
year = {2025},
doi = {10.1016/j.contraception.2025.110830}
}
EUVIMED